Fluence-modulated proton CT optimized with patient-specific dose and variance objectives for proton dose calculation.


Journal

Physics in medicine and biology
ISSN: 1361-6560
Titre abrégé: Phys Med Biol
Pays: England
ID NLM: 0401220

Informations de publication

Date de publication:
02 03 2021
Historique:
pubmed: 6 2 2021
medline: 3 8 2021
entrez: 5 2 2021
Statut: epublish

Résumé

Particle therapy treatment planning requires accurate volumetric maps of the relative stopping power, which can directly be acquired using proton computed tomography (pCT). With fluence-modulated pCT (FMpCT) imaging fluence is concentrated in a region-of-interest (ROI), which can be the vicinity of the treatment beam path, and imaging dose is reduced elsewhere. In this work we present a novel optimization algorithm for FMpCT which, for the first time, calculates modulated imaging fluences for joint imaging dose and image variance objectives. Thereby, image quality is maintained in the ROI to ensure accurate calculations of the treatment dose, and imaging dose is minimized outside the ROI with stronger minimization penalties given to imaging organs-at-risk. The optimization requires an initial scan at uniform fluence or a previous x-ray CT scan. We simulated and optimized FMpCT images for three pediatric patients with tumors in the head region. We verified that the target image variance inside the ROI was achieved and demonstrated imaging dose reductions outside of the ROI of 74% on average, reducing the imaging dose from 1.2 to 0.3 mGy. Such dose savings are expected to be relevant compared to the therapeutic dose outside of the treatment field. Treatment doses were re-calculated on the FMpCT images and compared to treatment doses re-recalculated on uniform fluence pCT scans using a 1% criterion. Passing rates were above 98.3% for all patients. Passing rates comparing FMpCT treatment doses to the ground truth treatment dose were above 88.5% for all patients. Evaluation of the proton range with a 1 mm criterion resulted in passing rates above 97.5% (FMpCT/pCT) and 95.3% (FMpCT/ground truth). Jointly optimized fluence-modulated pCT images can be used for proton dose calculation maintaining the full dosimetric accuracy of pCT but reducing the required imaging dose considerably by three quarters. This may allow for daily imaging during particle therapy ensuring a safe and accurate delivery of the therapeutic dose and avoiding excess dose from imaging.

Identifiants

pubmed: 33545701
doi: 10.1088/1361-6560/abe3d2
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

064001

Auteurs

J Dickmann (J)

Department of Medical Physics, Fakultät für Physik, Ludwig-Maximilians-Universität München (LMU Munich), D-85748 Garching bei München, Germany.

F Kamp (F)

Department of Radiation Oncology, University Hospital, LMU Munich, D-81377 Munich, Germany.

M Hillbrand (M)

Institut für Radio-Onkologie, Kantonsspital Graubünden, CH-7000 Chur, Switzerland.

S Corradini (S)

Department of Radiation Oncology, University Hospital, LMU Munich, D-81377 Munich, Germany.

C Belka (C)

Department of Radiation Oncology, University Hospital, LMU Munich, D-81377 Munich, Germany.
German Cancer Consortium (DKTK), D-81377 Munich, Germany.

R W Schulte (RW)

Division of Biomedical Engineering Sciences, Loma Linda University, Loma Linda, CA 92354, United States of America.

K Parodi (K)

Department of Medical Physics, Fakultät für Physik, Ludwig-Maximilians-Universität München (LMU Munich), D-85748 Garching bei München, Germany.

G Dedes (G)

Department of Medical Physics, Fakultät für Physik, Ludwig-Maximilians-Universität München (LMU Munich), D-85748 Garching bei München, Germany.

G Landry (G)

Department of Medical Physics, Fakultät für Physik, Ludwig-Maximilians-Universität München (LMU Munich), D-85748 Garching bei München, Germany.
Department of Radiation Oncology, University Hospital, LMU Munich, D-81377 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH